Accelerate Diagnostics to Host Call to Review First Quarter 2021 Results

Rhea-AI Summary

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its 2021 first quarter financial results. Interested participants can join by phone at +1.877.883.0383, entering Elite Entry Number: 4747452, or listen via webcast at ir.axdx.com. A replay will be accessible via phone and the website until August 6, 2021, and May 27, 2021, respectively. Accelerate Diagnostics focuses on solutions for antibiotic resistance and sepsis through its FDA-cleared systems that expedite antibiotic susceptibility testing.

TUCSON, Ariz., May 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time to review 2021 first quarter financial results.

To listen by phone, dial +1.877.883.0383 and enter Elite Entry Number: 4747452. International participants may dial +1.412.902.6506. Please dial in 10–15 minutes prior to the start of the conference.

This conference call will also be webcast and can be accessed from the company's website at ir.axdx.com. A replay of the audio webcast will be available until August 6, 2021.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 10154554 until May 27, 2021.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno^® system and Accelerate PhenoTest^® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-to-host-call-to-review-first-quarter-2021-results-301284788.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When is the Accelerate Diagnostics conference call to discuss first quarter results?

The conference call is scheduled for May 6, 2021, at 4:30 p.m. Eastern Time.

How can I listen to the Accelerate Diagnostics conference call?

You can listen by calling +1.877.883.0383 or via webcast at ir.axdx.com.

Is there a replay available for the Accelerate Diagnostics conference call?

Yes, a replay will be available until August 6, 2021, for the webcast and until May 27, 2021, for the phone replay.

What are the main products of Accelerate Diagnostics?

Accelerate Diagnostics specializes in in vitro diagnostics, particularly the Accelerate Pheno® system, which automates antibiotic susceptibility testing.

What is the significance of Accelerate Diagnostics' solutions?

Their solutions aim to combat antibiotic resistance and sepsis by providing faster testing results, enabling quicker and more effective treatment.